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William Craig (WC): Professor Cars, you said that there are 
only limited human data on the duration of therapy in 
relation to bacteriological eradication. However, in vitro 
studies and animal models of infection appear to show that 
pathogens can be eradicated in a short period of time 
provided effective antimicrobial agents are used. Do you 
think that the situation will be markedly different in 
humans, and that we will need longer courses of antibiotic 
treatment? 
Otto Cars (OC): No, I don’t think the situation will be 
that different. In urinary tract infections, for example, the 
length of treatment can be reduced to 3 days or less. When 
we use such treatment periods, however, some bacteriolo- 
gical efficacy is lost, and more patients have persistent 
pathogens at follow-up, though I don’t believe that this 
actually has any real clinical impact. Current recommenda- 
tions for treatment duration are too rigid and tend to be 
based on old data-or even on no data. What we probably 
need to do is to weigh up what we lose, in terms of 
bacteriological efficacy, by reducing the duration of 
treatment, against what we are likely to gain, and to tailor 
treatment more individually. By way of illustration, 
imagine a patient who has had an infection for a long 
period of time, in whom the bacterial load is high. This 
patient probably needs to have a longer course of treatment 
than someone who has only been ill for a few days. 
WC: Professor Garau, what duration of treatment do we 
need in pneumonia? 
Javier Garau (JG): Well, as we have already heard, data 
from animal models and from studies in otherwise healthy 
individuals show that you can eradicate pathogens quite 
quickly providing you use a sufficient dose. I do think that, 
for community-acquired pneumonia, it may be possible to 
shorten the duration of therapy, though it will be difficult to 
demonstrate eradication clinically, as we seldom know the 
causative pathogen. In my own experience, I have found 
that a 3-day course of penicillin eradicates pathogens 
effectively in cases of pneumococcal pneumonia, pro- 
viding that the patient does not have pre-existing alveolar 
disease. 
WC: Newer antimicrobial agents have been evaluated 
over shorter treatment periods. Unfortunately, such studies 
are not normally performed using older-and often cheaper 
-agents. Regulatory authorities require us to continue 
using these older agents on the basis on which they were 
approved. It is, therefore, difficult to perform a study that 
uses these agents in a way that falls outside of the criteria 
on which they were first approved. I suppose I have to 
throw the ball back to the pharmaceutical companies to see 
whether they would consider performing a study in which 
they compared a new product with an older one, both given 
over a short treatment period. 
Question from the audience: Are problems with resistant 
pneumococci just beginning to emerge? Also, is the infective 
potential of a multi-drug-resistant pneumococcus (DRSP) 
the same as that of a susceptible one? 
0954-6111/01/OAOOS26+2 $35.00/O 
JG: In response to your first question, penicillin-resistant 
pneumococci have been found in Western countries since 
the early 1980s and, currently, they are found all over the 
world. The resistant pneumococcus is a global problem 
and, though prevalence rates vary from country to country, 
the overall prevalence is high. So, of course, it is something 
that we have to take into consideration on an everyday 
basis. 
As I understand it, your second question is about 
whether DRSP are more or less virulent-I believe 
they are less virulent. In mice, we know that the most 
virulent serotypes are not the ones that carry penicillin 
resistance. The best example is the serotype 3 pneumococ- 
GUS. A single colony of this can kill a mouse, but if we use 
serotypes 23, 19, or 14, we need a much higher concentra- 
tion of inoculum to produce disease. DRSP tend to occur 
more commonly in patients with underlying immune 
problems, in whom they cause invasive disease-this occurs 
far less commonly in otherwise healthy individuals. A 
recent study in France (1) addressed the complexities of the 
relationship between virulence, serotype and penicillin 
resistance, and one of the things the investigators found is 
that penicillin resistance tends to cluster in strains that are 
less virulent. 
Comment from the audience: I would like to agree with 
what Professor Garau has said. It has also been our 
experience that, in mice at least, you have to use 
immunocompromised animals to observe growth of peni- 
cillin-resistant pneumococci. This is markedly different 
to what we have observed for penicillin-susceptible 
strains. 
Comment from the audience: I would just like to say that, 
while we do have some evidence from animal models that 
this is the case, I think the reality is that, in humans, most 
patients are compromised in some way. There are a great 
number of papers that show that many adults with severe 
pneumococcal pneumonia have underlying disease. There 
was, in fact, a recent paper in Clinical Infectious Diseases (2) 
that demonstrated a positive association between severity 
of disease and resistance. In other words, the most severe 
disease was found in those patients who were infected with 
resistant strains. I don’t think we really have any objective 
evidence, as yet, to conclude that these resistant strains are 
weaker in the human host. 
Question from the audience: Does the use of antibiotics in 
the food industry have implications for the development of 
resistance in human pathogens? 
OC: I am quite convinced that the heavy use of 
antibiotics in growth promotion has contributed to the 
development of resistance in enterococci, for example, 
vancomycin-resistant enterococci. But there are only a 
limited number of species that can transmit disease to 
humans and cause clinical infection. I think, to answer the 
question briefly, human medicine causes the most prob- 
lems. However, this being one ecological system, we need to 
consider all aspects of unnecessary use. 
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WC: Yes, I agree. With respect to respiratory pathogens 
-which have been our primary focus today-I think the 
antibiotic resistance is a human use problem, not related 
much at all to antibiotic use in animals. On the other hand, 
if we were looking at Salmonella, Campylobacter or other 
such bacteria, then the use of antibiotics in animals would 
clearly be more relevant. 
Question from audience: I would like to know your 
opinion on the new oxazolidinone that is claimed to be 
effective against not only vancomycin-resistant enterococci 
and methicillin-resistant Staphylococcus aureus, but also 
against pneumococci and streptococci. How do we use this 
new agent? Should we reserve it for persistent pathogens or 
do you think we should use it on a more liberal basis? 
WC: I think the cost of such a new agent will restrict its 
use on an everyday basis; however, I think we do need to 
address this issue with other agents, such as the newer 
fluoroquinolones which are available more cheaply. The 
question is, should we be using the more potent agents up 
front to try and reduce the long-term incidence of 
resistance, or do we wait until resistance develops before 
we use them? Mathematical models suggest that it is 
probably more appropriate to use the most potent agent 
early on, thereby preventing resistance from developing in 
the first place. 
Question from the audience: In addition to restricting 
antibiotic use, do you think we need other measures to help 
control resistance? 
JG: Obviously, this is a multi-factorial problem that will 
require a multi-factorial solution. I think that rational 
antibiotic use as well as measures for minimizing the spread 
of resistant pathogens are key-one may be more relevant 
than the other depending on the circumstances. For 
example, in the intensive care unit, a policy for minimizing 
spread may be more relevant than an antibiotic prescribing 
policy. 
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